The Overheard at Frequency podcast explores issues surrounding hearing loss and the unmet needs of the patient community. Hosted by Colleen Chapman, Senior Director of Patient Advocacy and Government Affairs at Frequency Therapeutics, the podcast brings timely and interesting stories about hearing science, advocacy and innovation to our listeners.

In part 1 of this two-part episode, Colleen sits down with Carl LeBel, PhD, Frequency’s Chief Development Officer, to discuss a new clinical study of FX-322 that is currently enrolling subjects, new learnings from previous studies and how we are incorporating those learnings into ongoing and future trials – all with the goal of potentially bringing the first hearing loss therapeutic to patients.